NCT Number,Study Title,Study URL,Acronym,Study Status,Brief Summary,Study Results,Conditions,Interventions,Primary Outcome Measures,Secondary Outcome Measures,Other Outcome Measures,Sponsor,Collaborators,Sex,Age,Phases,Enrollment,Funder Type,Study Type,Study Design,Other IDs,Start Date,Primary Completion Date,Completion Date,First Posted,Results First Posted,Last Update Posted,Locations,Study Documents
NCT00436839,Taxotere Prostate Cancer New Indication Registration Trial in China,https://clinicaltrials.gov/study/NCT00436839,,COMPLETED,To compare overall survival after receiving mitoxantrone and prednisone or docetaxel and prednisone in subjects with hormone-refractory metastatic prostate cancer.,NO,Prostatic Neoplasms,DRUG: Docetaxel|DRUG: Mitoxantrone|DRUG: Prednisone,"Efficacy: Overall survival, From beginning to end of the study|Objective response rate of patients with measurable disease by Response Evaluation Criteria in Solid tumours, From beginning to end of study|Prostatic Specific Antigen response, From the beginning to the end of study|Pain response (McGill-Melzack Scale), From beginning to end of study|Time to progression, From beginning to end of study|Adverse event, From beginning to end of study|Quality Of Life: Functional assessment of chronic illness therapy-prostate questionnaire will be used, From beginning to end of study",,,Sanofi,,MALE,"CHILD, ADULT, OLDER_ADULT",PHASE3,228,INDUSTRY,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,DOCET_L_01833,2007-01,2012-06,2012-06,2007-02-19,,2012-07-09,"Sanofi-Aventis Administrative Office, Shanghai, China",
